|
|
Untitled Document
| |
Cardiovascular Drug Development
Course # I31
December 05 - December 07, 2005
Start - 7:30
Finish - 12:30
|
|
Hotel Information:
Wyndham Boston
89 Broad Street
Boston, MA 02110
Toll-Free: (800) 996-3426
Phone: (617) 556-2000
Fax: (617) 348-1444
Discounted Hotel Room Rate: $129
Reserve Your Hotel Room:
call hotel and mention PERI discounted rate
Deadline to Receive Discounted Rate: 11/14/05
Rate: $
129
Deadline for Group Rate:
2005-11-14
Hotel Policy
|
Registration Rate:
$1,495.00 Register by 10/24/05
$1,695.00 Register after 10/24/05
Cancellation Date: 11/21/05 (Cancellation fee is determined by date cancelled.)
Course Completed
Registration Policy
Continuing Education Credit:
ACPE:
708-000-05-004-L01 (1.775 CEU)
Initial Release Date:
12/5/05
CBRN:
N/A
CME:
17.75 Hours of Category 1 Credit
VNA:
04-04-05 21.30 Contact Hours
Continuing Education Policy
|
| |
Course Description:
This course will provide an overview of the cardiac anatomy, physiology, epidemiology, and diagnosis for hypertension, coronary artery disease, congestive heart failure, and cardiac arrhythmia. Emphasis will be on designing clinical trials and developing drug therapy through interactive sessions and hands-on workshops. These sessions will also provide a review of clinical trials issues and the importance of addressing these issues early in cardiovascular drug development.
|
Who Should Attend:
This course is directed towards individuals responsible for cardiovascular drugs and those interested. This would also include project managers, clinical monitors, and directors of clinical research and development, and decision makers in pharmaceutical R&D.
|
Educational Objectives:
Upon completion of this course, participants should be able to:
- Describe the basic anatomy, physiology, epidemiology, and diagnosis of the cardiovascular disease
- Discuss new therapeutic approaches
- Identify issues involved in designing and analyzing cardiovascular clinical trials
- Gain understanding of the regulatory issues related to cardiovascular drug development
- Discuss drug safety and how to monitor them in clinical trials
- Interact with experts from FDA and the pharmaceutical industry
|
Key Topics:
- Cardiovascular Disease: An overview
- New Therapeutic Approaches to Cardiovascular Disease Management
- Design of Cardiovascular Clinical Trials
- Statistical Considerations
- Drug Safety and Monitoring
- Workshop: Clinical Trial Design
- Regulatory Considerations
|
|
Course Director(s):
Hans deRuyter MD, FACP, FRCP- Course Director
Senior Medical Director
PharmaNet
Alan M Ezrin, PhD
Chief Scientific Officer
Cardiome Pharma Corp
Allan Haberman Ph.D
Prinicipal
Haberman Associates
Jonathan F. Plehn MD
Director, Heart Failure Services
Division of Cardiology, George Washington Medical Center
Medical Faculty Associates
Cynthia Siu PhD, MBA
Data Power (DP), Inc.
Joel Freiman, MD, MPH
Tom Garland MD
Senior Medical Director
PharmaNet
Jean T Barbey MD
Medical Director,
Core Cardiolgy Laboratory
Medifacts International
|
|
Contact Course Manager:
Course Manager
|
| |
|
|
|
PERI reserves the right to change agenda
items and instructors without notice to accommodate
situations beyond its control.
|
|
|
